BioSpace News Archive

Press Releases

ChemoMetec enters collaboration agreement with Roche Diagnostics

August 10, 2026

·

1 min read

Press Releases

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

August 10, 2026

·

19 min read

Bright colorful eye pattern. Hand drawn illustration by brush strokes. For meditation, contemplation. Yoga, reiki, spiritual practices.

Psychedelics

All eyes on psychedelic drugmakers as Definium, Compass near major catalysts

Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.

August 10, 2026

·

3 min read

·

Gabrielle Masson

Brown wallet with green dollar bills and coins against a white background. Business and backing design element.

Mergers & acquisitions

Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline

Jazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.

August 10, 2026

·

2 min read

·

Gabrielle Masson

Economic Recovery. Change from loss to profit. Portfolio adjustment in economic crisis or stock market. Businessman jumping from falling arrow to rising arrow. Illustration

Cystic fibrosis

Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.

August 10, 2026

·

2 min read

·

Michael Gibney

Press Releases

AQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial, Results to Be Presented at Major Heart Failure Conference This Fall

August 10, 2026

·

3 min read

Press Releases

Lifespan Vision Ventures Leads Remedium Bio’s Series A Financing